JAMA oncology, 2374-2437

Journal

  1. 2020
  2. Familial MRI Screening (FaMRIsc) Study group, Geuzinge, H. A., Obdeijn, I-M., Rutgers, E. J. T., Saadatmand, S., Mann, R. M., Oosterwijk, J. C., Tollenaar, R. A. E. M., de Roy van Zuidewijn, D. B. W., Lobbes, M. B. I., van 't Riet, M., Hooning, M. J., Ausems, M. G. E. M., Loo, C. E., Wesseling, J., Luiten, E. J. T., Zonderland, H. M., Verhoef, C., Heijnsdijk, E. A. M., ... de Koning, H. J. (2020). Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA oncology, 6(9), 1381-1389. https://doi.org/10.1001/jamaoncol.2020.2922
  3. Rovers, K. P., Bakkers, C., van Erning, F. N., Burger, J. W. A., Nienhuijs, S. W., Simkens, G. A. A. M., Creemers, G-J. M., Hemmer, P. H. J., Punt, C. J. A., Lemmens, V. E. P. P., Tanis, P. J., & de Hingh, I. H. J. T. (2020). Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. JAMA oncology, 6(8), [202701]. https://doi.org/10.1001/jamaoncol.2020.2701
  4. Steenbruggen, T. G., Steggink, L. C., Seynaeve, C. M., van der Hoeven, J. J. M., Hooning, M. J., Jager, A., Konings, I. R., Kroep, J. R., Smit, W. M., Tjan-Heijnen, V. C. G., van der Wall, E., Bins, A. D., Linn, S. C., Schaapveld, M., Jacobse, J. N., van Leeuwen, F. E., Schröder, C. P., van Tinteren, H., de Vries, E. G. E., ... Gietema, J. A. (2020). High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes 20-Year Follow-up of a Phase 3 Randomized Clinical Trial: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. JAMA oncology, 6(4), 528-534. https://doi.org/10.1001/jamaoncol.2019.6276
  5. 2019
  6. DCOG LATER Study Grp, Kok, J. L., Teepen, J. C., van der Pal, H. J., van Leeuwen, F. E., Tissing, W. J. E., Neggers, S. J. C. M. M., Loonen, J. J., Louwerens, M., Versluys, B., van den Heuvel-Eibrink, M., van Dulmen-den Broeder, E., Jaspers, M. M. W., van Santen, H. M., van der Heiden-van der Loo, M., Janssens, G. O., Maduro, J. H., Bruggink, A. H., Jongmans, M. C., ... Ronckers, C. M. (2019). Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer. JAMA oncology, 5(5), 671-680. https://doi.org/10.1001/jamaoncol.2018.6862
  7. Bex, A., Mulders, P., Jewett, M., Wagstaff, J., Van Thienen, J. V., Blank, C. U., Van Velthoven, R., Del Pilar Laguna, M., Wood, L., Van Melick, H. H. E., Aarts, M. J., Lattouf, J. B., Powles, T., De Jong, I. J., Rottey, S., Tombal, B., Marreaud, S., Collette, S., Collette, L., & Haanen, J. (2019). Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA oncology, 5(2), 164-170. https://doi.org/10.1001/jamaoncol.2018.5543
  8. 2018
  9. Targeted Alpha Therapy Working Grp, Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Linden, O., Noordzij, W., Park, J., & Saad, F. (2018). Targeted Alpha Therapy, an Emerging Class of Cancer Agents A Review. JAMA Oncol, 4(12), 1765-1772. https://doi.org/10.1001/jamaoncol.2018.4044
  10. European Society for Medical Oncology Magnitude of Clinical Benefit Scale Working Group (2018). Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. JAMA oncology, 4(10), 1437. https://doi.org/10.1001/jamaoncol.2018.3264
  11. Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., Jakovljevic, M., Khader, Y., Linn, S., Lad, D., Mantovani, L., Vuong Minh Nong, Mokdad, A., Naghavi, M., Postma, M., ... Fitzmaurice, C. (2018). Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016. JAMA oncology, 4(9), 1221-1227. https://doi.org/10.1001/jamaoncol.2018.2128
  12. 2016
  13. Boekhout, A. H., Gietema, J. A., Kerklaan, B. M., van werkhoven, E. D., Altena, R., Honkoop, A., Los, M., Smit, W. M., Nieboer, P., Smorenburg, C. H., Mandigers, C. M. P. W., van der Wouw, A. J., Kessels, L., van der Velden, A. W. G., Ottevanger, P. B., Smilde, T., de Boer, J., van Veldhuisen, D. J., Kema, I. P., ... Schellens, J. H. M. (2016). Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA oncology, 2(8), 1030-1037. https://doi.org/10.1001/jamaoncol.2016.1726
  14. 2013
  15. Mohamadkhani, A., Naderi, E., Sharafkhah, M., Fazli, H. R., Moradzadeh, M., & Pourshams, A. (2013). Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. JAMA oncology, 2013, [738915]. https://doi.org/10.1155/2013/738915

ID: 37132924